2/5
04:05 pm
sprb
Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy’s Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)
Low
Report
Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy’s Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)
2/3
08:36 am
sprb
Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team [Yahoo! Finance]
Medium
Report
Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team [Yahoo! Finance]
2/3
08:00 am
sprb
Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team
Medium
Report
Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team
1/28
08:00 am
sprb
Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™
Medium
Report
Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™
1/19
01:53 am
sprb
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration [Yahoo! Finance]
Medium
Report
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration [Yahoo! Finance]
1/18
07:02 pm
sprb
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration
Medium
Report
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration
1/8
08:00 am
sprb
Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital
Medium
Report
Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital
12/27
01:05 am
sprb
Spruce Biosciences (NASDAQ:SPRB) was downgraded by analysts at
Wall Stre
Low
Report
Spruce Biosciences (NASDAQ:SPRB) was downgraded by analysts at
Wall Stre
12/23
07:17 am
sprb
Spruce Biosciences (NASDAQ:SPRB) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating on the stock.
Low
Report
Spruce Biosciences (NASDAQ:SPRB) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating on the stock.
12/22
08:02 am
sprb
Spruce Biosciences (NASDAQ:SPRB) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $220.00 price target on the stock.
High
Report
Spruce Biosciences (NASDAQ:SPRB) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $220.00 price target on the stock.
12/15
08:20 am
sprb
Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors [Yahoo! Finance]
Medium
Report
Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors [Yahoo! Finance]
12/15
08:00 am
sprb
Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors
Medium
Report
Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors
12/6
01:36 am
sprb
Spruce Biosciences (NASDAQ:SPRB) was upgraded by analysts at
Wall Street
Low
Report
Spruce Biosciences (NASDAQ:SPRB) was upgraded by analysts at
Wall Street
12/4
07:18 am
sprb
Spruce Biosciences (NASDAQ:SPRB) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.
Low
Report
Spruce Biosciences (NASDAQ:SPRB) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.
12/3
08:44 am
sprb
Spruce Biosciences (NASDAQ:SPRB) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $160.00 price target on the stock.
Medium
Report
Spruce Biosciences (NASDAQ:SPRB) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $160.00 price target on the stock.
11/18
01:20 pm
sprb
Spruce Biosciences (NASDAQ:SPRB) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Spruce Biosciences (NASDAQ:SPRB) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/15
01:42 am
sprb
Spruce Biosciences (NASDAQ:SPRB) was upgraded by analysts at
Wall Street
Medium
Report
Spruce Biosciences (NASDAQ:SPRB) was upgraded by analysts at
Wall Street
11/12
01:30 pm
sprb
Spruce Biosciences (NASDAQ:SPRB) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Spruce Biosciences (NASDAQ:SPRB) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/11
09:06 am
sprb
Spruce Biosciences (NASDAQ:SPRB) had its price target raised by analysts at Citizens Jmp from $254.00 to $259.00. They now have a "market outperform" rating on the stock.
Low
Report
Spruce Biosciences (NASDAQ:SPRB) had its price target raised by analysts at Citizens Jmp from $254.00 to $259.00. They now have a "market outperform" rating on the stock.
11/11
08:44 am
sprb
Spruce Biosciences (NASDAQ:SPRB) was given a new $259.00 price target on by analysts at JMP Securities.
Low
Report
Spruce Biosciences (NASDAQ:SPRB) was given a new $259.00 price target on by analysts at JMP Securities.
11/11
07:03 am
sprb
Spruce Biosciences (NASDAQ:SPRB) had its "market perform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Spruce Biosciences (NASDAQ:SPRB) had its "market perform" rating reaffirmed by analysts at Citigroup Inc..
11/10
04:32 pm
sprb
Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates [Yahoo! Finance]
Low
Report
Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates [Yahoo! Finance]
11/10
04:05 pm
sprb
Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Low
Report
Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates